[Chemotherapy of malignant bone tumors].
In several primary malignant tumors significant improvement of formely bad prognosis has been achieved by the introduction of new cytostatic compounds and the study of new cytostatic combination regimens. Adjuvant chemotherapy in osteosarcoma and Ewing's sarcoma led to remarkable increase in survival rates. Leaning on natural history and on remission rates reached by cytostatic treatment in metastasizing stages of disease, proposals for adjuvant chemotherapy are made and chemotherapy regimen appliable on out-patient basis is described.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy*; D002813:Chondrosarcoma / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005354:Fibrosarcoma / Q000188:drug therapy; D005870:Giant Cell Tumors / Q000188:drug therapy; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000188:drug therapy*; D011379:Prognosis; D012512:Sarcoma, Ewing / Q000188:drug therapy
D000970:Antineoplastic Agents
Chemotherapie maligner Knochentumoren